RxDoctor Payments Data

Robert Stagliano, DO

Family Medicine · Collingswood, NJNPI 1134158108

Payments from drug & device makers

$5,665in general payments, 2019–2025

Across 291 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$703
  • AstraZeneca$689
  • Novo Nordisk$423
  • Amarin Pharma, Inc.$356
  • Pfizer$352
  • GSK$305
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,647100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,665 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$106,533
Medicare patients
170
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$89,861
Synjardy XrEmpagliflozin/Metformin Hcl35$48,496
JardianceEmpagliflozin26$45,653
VascepaIcosapent Ethyl24$22,940
GlyxambiEmpagliflozin/Linagliptin18$19,752
TradjentaLinagliptin15$19,215
JanuviaSitagliptin Phosphate12$14,487
Icosapent Ethyl14$7,796
Rosuvastatin Calcium288$5,693
Atorvastatin Calcium163$2,473
Ezetimibe-SimvastatinEzetimibe/Simvastatin11$2,431
Metoprolol Succinate150$2,431
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med25$2,248
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid12$2,228
Levothyroxine Sodium160$2,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi, Tradjenta$290$133,11594 claims
PfizerEliquis$352$89,86155 claims
MerckJanuvia$122$14,48712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Collingswood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →